Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial-Reference-Cited by-同舟云学术

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Published:2016-12 Issue:12 Volume:17 Page:1683-1696
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gettinger Scott N,Bazhenova Lyudmila A,Langer Corey J,Salgia Ravi,Gold Kathryn A,Rosell Rafael,Shaw Alice T,Weiss Glen J,Tugnait Meera,Narasimhan Narayana I,Dorer David J,Kerstein David,Rivera Victor M,Clackson Timothy,Haluska Frank G,Camidge David Ross

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. New driver mutations in non-small-cell lung cancer;Pao;Lancet Oncol,2011

2. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology;Hallberg;Nat Rev Cancer,2013

3. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience;Sholl;J Thorac Oncol,2015

4. A pan-cancer review of ALK mutations: implications for carcinogenesis and therapy;Yau;Curr Cancer Drug Targets,2015

5. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

Cited by 312 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-silico QSAR Modeling for Identification of Novel Anticancer Agent as;PHYS CHEM RES;2024

2. Cancer-associated fibroblasts confer ALK inhibitor resistance inEML4-ALK-driven lung cancer via concurrent integrin and MET signaling;2024-08-28

3. Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study;ESMO Open;2024-08

4. Discordant ALK Status in Non-Small Cell Lung Carcinoma: A Detailed Reevaluation Comparing IHC, FISH, and NGS Analyses;International Journal of Molecular Sciences;2024-07-26

5. Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP;Journal of Pathology and Translational Medicine;2024-07-15